

Policy References: [Local Coverage Determination Nebulizers \(L33370\)](#) and [Policy Article \(A52466\)](#)

Documentation References: [Standard Documentation Requirements Policy Article \(PA\) A55426](#)

The treating clinician must complete the following items:

- [Standard Written Order \(SWO\)](#)
- Medical record documentation requirements (see below)

Medical Documentation

Small Volume Nebulizers, Related Compressor, and FDA-Approved Inhalation Drugs

- Refer to the LCD (link above) for covered drugs for covered medical conditions, which include obstructive pulmonary disease, cystic fibrosis, bronchiectasis, HIV, pneumocystosis, complications of organ transplants, and persistent thick or tenacious pulmonary secretions.

Large Volume Nebulizer, Related Compressor, and Water or Saline

- To deliver required humidity for thick, tenacious secretions to beneficiaries with cystic fibrosis, bronchiectasis, tracheostomy, or tracheobronchial stents.

Filtered Nebulizer and Compressor

- To deliver pentamidine to beneficiaries with HIV, pneumocystosis, or complications of organ transplants (refer to LCD link above)

Small Volume Ultrasonic Nebulizer or Controlled Dose Inhalation Drug Delivery System

To deliver treprostinil or iloprost to beneficiaries who meet:

- Beneficiary has a diagnosis of pulmonary artery hypertension; **and**
- Pulmonary hypertension is not secondary to pulmonary venous hypertension or disorders of the respiratory system; **and**
- Beneficiary has primary pulmonary hypertension or pulmonary hypertension which is secondary to connective tissue disease, thromboembolic disease of the pulmonary arteries, HIV infection, cirrhosis, or anorexigens (diet drugs), or congenital left to right shunts; **and**
 - Pulmonary hypertension has progressed despite maximal medical and/or surgical treatment of the identified condition; **and**
 - Mean pulmonary artery pressure is > 25 mm Hg at rest or > 30 mm Hg with exertion; **and**
 - Beneficiary has significant symptoms from the pulmonary hypertension (i.e., severe dyspnea on exertion, and either fatigability, angina, or syncope); **and**
 - Treatment with oral calcium channel blocking agents has been tried and failed, or has been considered and ruled out.

The content of this document was prepared as an educational tool and is not intended to grant rights or impose obligations. Use of this document is not intended to take the place of either written law or regulations. Suppliers are reminded to review the Local Coverage Determination and Policy Article for specific documentation guidelines.